Literature DB >> 10703757

Role of norepinephrine in depression.

P L Delgado1, F A Moreno.   

Abstract

This article reviews the role of norepinephrine (NE) and serotonin (5-HT) in depression and the therapeutic effects of antidepressant drugs from the perspective of human neurotransmitter depletion studies. The data reviewed suggest that both noradrenergic and serotonergic systems are involved in antidepressant action, but the specific impairment that underlies depression is unclear and is likely to vary among patients. Results from neurotransmitter depletion studies in depressed patients who have responded to treatment suggest that, while interactions between NE and 5-HT are likely, neither of these 2 neurotransmitter systems is the final common pathway for the therapeutic effect of antidepressant drugs. NE-selective antidepressant drugs appear to be primarily dependent on the availability of NE for their effects. Likewise, 5-HT-selective antidepressants appear to be primarily dependent on the availability of 5-HT for their effects. Antidepressants that cause effects on both noradrenergic and serotonergic systems-such as mirtazapine-may be dependent on the availability of both neurotransmitters for their effects. Neither 5-HT nor NE depletion induced clinical depression in healthy subjects or worsened depression in unmedicated symptomatic patients with major depression. This finding suggests that the cause of depression is more complex than just an alteration in the levels of 5-HT and/or NE. For some patients, depression may be more directly caused by dysfunction in brain areas or neuronal systems modulated by monoamine systems. We propose that antidepressant drugs may enhance neurotransmission in normal noradrenergic or serotonergic neurons and, through a time-dependent but as yet undiscovered process, restore function to brain areas modulated by monoamine neurons. Future research should focus on understanding the adaptive changes that follow enhancement of synaptic levels of monoamines in neuronal circuits of the frontal cortex, amygdala, and hippocampus. Research investigating the neurobiology of depression may be more informed if the focus is shifted to investigating areas of the brain modulated by monoamine systems rather than the monoamine systems themselves.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10703757

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  54 in total

1.  Behavior analysis in the era of medicalization: the state of the science and recommendations for practitioners.

Authors:  W Joseph Wyatt
Journal:  Behav Anal Pract       Date:  2009

Review 2.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

3.  Effects of chronic antidepressant treatments in a putative genetic model of vulnerability (Roman low-avoidance rats) and resistance (Roman high-avoidance rats) to stress-induced depression.

Authors:  Giovanna Piras; Maria A Piludu; Osvaldo Giorgi; Maria G Corda
Journal:  Psychopharmacology (Berl)       Date:  2013-07-30       Impact factor: 4.530

4.  Metabolomic differences in heart failure patients with and without major depression.

Authors:  David C Steffens; K Ranga R Krishnan; Edward D Karoly; Matthew W Mitchell; Christopher M O'Connor; Rima Kaddurah-Daouk
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-01-25       Impact factor: 2.680

Review 5.  Exercise and the treatment of clinical depression in adults: recent findings and future directions.

Authors:  Alisha L Brosse; Erin S Sheets; Heather S Lett; James A Blumenthal
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

6.  An altered spinal serotonergic system contributes to increased thermal nociception in an animal model of depression.

Authors:  Antonio Rodríguez-Gaztelumendi; María Luisa Rojo; Angel Pazos; Alvaro Díaz
Journal:  Exp Brain Res       Date:  2014-03-01       Impact factor: 1.972

Review 7.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

8.  The contribution of the locus coeruleus-norepinephrine system in the emergence of defeat-induced inflammatory priming.

Authors:  Julie E Finnell; Casey M Moffitt; L Ande Hesser; Evelynn Harrington; Michael N Melson; Christopher S Wood; Susan K Wood
Journal:  Brain Behav Immun       Date:  2019-01-29       Impact factor: 7.217

9.  Confederates in the Attic: Posttraumatic Stress Disorder, Cardiovascular Disease, and the Return of Soldier's Heart.

Authors:  J Douglas Bremner; Matthew T Wittbrodt; Amit J Shah; Bradley D Pearce; Nil Z Gurel; Omer T Inan; Paolo Raggi; Tené T Lewis; Arshed A Quyyumi; Viola Vaccarino
Journal:  J Nerv Ment Dis       Date:  2020-03       Impact factor: 2.254

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.